Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on August 15, 2022. The filing serves to announce the company's financial results for the three and six months ended June 30, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the periods ended June 30, 2022.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It notes that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name is ReShape Lifesciences Inc., as the input metadata incorrectly listed "Vyome Holdings, Inc."
- Review Exhibit 99.1 (the Press Release dated August 15, 2022) for actual revenue, net loss, and cash position figures.
- Confirm the specific trading symbol RSLS on the Nasdaq Capital Market.
- Note that the financial data in this specific 8-K text is a reference only and does not contain the underlying numbers.